VTAMA® (tapinarof) cream 1% for the Treatment of Plaque Psoriasis in Adults

Dermavant CEO Todd Zavodnick discusses the recent approval of VTAMA ® (tapinarof) cream, 1% and how this first-in-class topical therapy brings long awaited change to the plaque psoriasis treatment landscape. 

Indication: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in subjects treated with VTAMA cream were folliculitis (red raised bumps around the hair pores), nasopharyngitis (pain or swelling in the nose and throat), contact dermatitis (skin rash or irritation, including itching and redness, peeling, burning, or stinging), headache, pruritus (itching), and influenza (flu).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For prescribing information, see below or visit https://www.vtama.com/PI/